Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Laura Cerchia

Showing results (21-30 of 79) with videos related to

Pageof 8
Sort By:
Pharmaceutics|January 21, 2022
Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications ThereofSarah Shigdar, Lisa Agnello, Monica Fedele, et al.
Nanomedicine (London, England)|June 24, 2026
Aptamer-functionalized nanoparticles for cancer targeting: conjugation strategies, current applications and future perspectivesLaura Cerchia, Emanuela Bua, Letizia Sambri, et al.
FEBS Letters|September 26, 2002
Nucleic acid aptamers in cancer medicineLaura Cerchia, Jörg Hamm, Domenico Libri, et al.
Cancers|September 1, 2019
Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell KillingMargherita Passariello, Simona Camorani, Cinzia Vetrei, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 21, 2009
Cell-specific aptamers for targeted therapiesLaura Cerchia, Paloma H Giangrande, James O McNamara, et al.
Oncotarget|May 8, 2018
Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κBSimona Camorani, Laura Cerchia, Monica Fedele, et al.
CNS & Neurological Disorders Drug Targets|August 26, 2009
Aptamers as innovative diagnostic and therapeutic agents in the central nervous systemVittorio de Franciscis, Carla Lucia Esposito, Silvia Catuogno, et al.
Pharmaceuticals (Basel, Switzerland)|October 11, 2016
Coupling Aptamers to Short Interfering RNAs as TherapeuticsLaura Cerchia, Carla Lucia Esposito, Simona Camorani, et al.
Cancers|April 13, 2023
Aptamer-Based Strategies to Boost Immunotherapy in TNBCLisa Agnello, Annachiara d'Argenio, Roberto Nilo, et al.
Scientific Reports|April 21, 2017
Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancersSimona Camorani, Elvira Crescenzi, Matteo Gramanzini, et al.
Pageof 8

Showing results (21-30 of 79) with videos related to

Sort By:
Pageof 8
Pharmaceutics|January 21, 2022
Profiling Cancer Cells by Cell-SELEX: Use of Aptamers for Discovery of Actionable Biomarkers and Therapeutic Applications ThereofSarah Shigdar, Lisa Agnello, Monica Fedele, et al.
Nanomedicine (London, England)|June 24, 2026
Aptamer-functionalized nanoparticles for cancer targeting: conjugation strategies, current applications and future perspectivesLaura Cerchia, Emanuela Bua, Letizia Sambri, et al.
FEBS Letters|September 26, 2002
Nucleic acid aptamers in cancer medicineLaura Cerchia, Jörg Hamm, Domenico Libri, et al.
Cancers|September 1, 2019
Novel Human Bispecific Aptamer-Antibody Conjugates for Efficient Cancer Cell KillingMargherita Passariello, Simona Camorani, Cinzia Vetrei, et al.
Methods in Molecular Biology (Clifton, N.J.)|April 21, 2009
Cell-specific aptamers for targeted therapiesLaura Cerchia, Paloma H Giangrande, James O McNamara, et al.
Oncotarget|May 8, 2018
Trabectedin modulates the senescence-associated secretory phenotype and promotes cell death in senescent tumor cells by targeting NF-κBSimona Camorani, Laura Cerchia, Monica Fedele, et al.
CNS & Neurological Disorders Drug Targets|August 26, 2009
Aptamers as innovative diagnostic and therapeutic agents in the central nervous systemVittorio de Franciscis, Carla Lucia Esposito, Silvia Catuogno, et al.
Pharmaceuticals (Basel, Switzerland)|October 11, 2016
Coupling Aptamers to Short Interfering RNAs as TherapeuticsLaura Cerchia, Carla Lucia Esposito, Simona Camorani, et al.
Cancers|April 13, 2023
Aptamer-Based Strategies to Boost Immunotherapy in TNBCLisa Agnello, Annachiara d'Argenio, Roberto Nilo, et al.
Scientific Reports|April 21, 2017
Aptamer-mediated impairment of EGFR-integrin αvβ3 complex inhibits vasculogenic mimicry and growth of triple-negative breast cancersSimona Camorani, Elvira Crescenzi, Matteo Gramanzini, et al.
Pageof 8